Job description:
 

We are at the centre of the rapidly growing cell and gene therapy sector. We deliver life-changing therapies to patients, and so can you.

We are currently recruiting for a Distribution Controller to join the Warehouse and Supply Chain (WSC) team.  The purpose of this role is to assist with the co-ordination and distribution of materials for Warehouse and Supply Chain. This includes all shipments and transportation inter site, customer, CMO and offsite storage of cold chain materials.

Our Warehouse and Supply Chain (WCS) team is critical to our Manufacturing success.  They make sure we have the consumables and reagents needed to make our customers products, which then go on to change the lives of millions of patients. This multi-functional team works together to support all our logistics needs.

Your responsibilities in this role would be:

• Pick and packing of all shipments and material movements to and from internal/eternal customers /CMO’s for Supply Chain
• Complete documentation to meet customs requirements, packing specifications, and compliance
• Update clinical trial inventory in IFS system
• Liaise with third parties in accordance with customer requirements
• Transport OXB materials to customers, Contract Manufacturing Organisations (CMO’s) and offsite storage
• Act as back up to the Senior Distribution Controller
• Maintain inventory of all critical shipping materials.

Profile description:

We are looking for:

• Experienced in distribution activities
• Understanding of GMP requirements
• Working Knowledge of ERP Systems
• Broad Knowledge of supply chain activities
• Experienced in the transportation of cold chain materials
• Broad Knowledge of inventory management
• Knowledge of distribution and transportation
• Knowledge of inventory management
• Demonstrate experience in a supply chain role preferably in GMP environment.
• Clean UK driving license.

About Us:

Oxford Biomedica is a quality and innovation-led viral vector CDMO (Contract Development and Manufacturing Organization) with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, we have more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.

Oxford Biomedica collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus, and adenoviral vectors. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods, and depth of regulatory expertise.

What’s in it for you:

• Highly competitive total reward packages
• Wellbeing programmes
• Development opportunities
• Welcoming, friendly, supportive colleagues
• A diverse and inclusive working environment
• Our values are: Deliver Innovation, Be Inspiring and Have Integrity
• State of the art laboratory and manufacturing facilities

Collaborate. Contribute. Change lives.

Closing date for applications is Tuesday 9th July 2024.

We offer:

Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies.  

Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy).  

Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.